Cultivar Capital Inc. Acquires 2,795 Shares of Danaher Corporation $DHR

Cultivar Capital Inc. acquired a new position in Danaher Corporation (NYSE:DHR) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,795 shares of the conglomerate’s stock, valued at approximately $619,000. Danaher accounts for about 0.4% of Cultivar Capital Inc.’s portfolio, making the stock its 17th biggest position.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DHR. Veery Capital LLC grew its position in shares of Danaher by 3.1% during the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock worth $350,000 after buying an additional 48 shares during the period. Studio Investment Management LLC grew its holdings in shares of Danaher by 3.3% during the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after buying an additional 51 shares during the last quarter. JDH Wealth Management LLC raised its holdings in shares of Danaher by 4.5% in the 1st quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $240,000 after acquiring an additional 55 shares during the last quarter. OLD Second National Bank of Aurora lifted its position in Danaher by 0.5% in the 1st quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock valued at $2,297,000 after acquiring an additional 57 shares in the last quarter. Finally, Adelphi Trust Co boosted its position in shares of Danaher by 2.5% during the third quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock valued at $524,000 after buying an additional 57 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 price target on shares of Danaher in a research report on Wednesday, July 22nd. Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Barclays boosted their target price on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. The Goldman Sachs Group raised their target price on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Finally, UBS Group began coverage on Danaher in a research note on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $235.41.

Danaher Price Performance

DHR traded up $1.81 on Wednesday, reaching $224.65. The company had a trading volume of 3,595,884 shares, compared to its average volume of 4,457,645. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a market cap of $157.93 billion, a price-to-earnings ratio of 39.90, a P/E/G ratio of 2.78 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The business has a 50 day simple moving average of $212.41 and a 200 day simple moving average of $195.13.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter last year, the company posted $0.77 EPS. The business’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.